[
    [
        {
            "time": "2018-03-13",
            "original_text": "Health Care Sector Update for 03/13/2018: ABBV,NBIX,EPZM,BLCM,MRK",
            "features": {
                "keywords": [
                    "Health Care",
                    "Sector Update",
                    "ABBV",
                    "NBIX",
                    "EPZM",
                    "BLCM",
                    "MRK"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 03/13/2018: ABBV,NBIX,EPZM,BLCM,MRK",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-03-13",
            "original_text": "Is This AbbVie's Next Blockbuster Drug?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Blockbuster Drug"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Is This AbbVie's Next Blockbuster Drug?",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-13",
            "original_text": "VHT, ABBV, BMY, DHR: ETF Outflow Alert",
            "features": {
                "keywords": [
                    "VHT",
                    "ABBV",
                    "BMY",
                    "DHR",
                    "ETF Outflow"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "VHT, ABBV, BMY, DHR: ETF Outflow Alert",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-13",
            "original_text": "Broadcom Can't Buy Qualcomm, But You Can",
            "features": {
                "keywords": [
                    "Broadcom",
                    "Qualcomm",
                    "Acquisition"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Broadcom Can't Buy Qualcomm, But You Can",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-13",
            "original_text": "Health Care Sector Update for 03/13/2018: ABBV, BLCM, EPZM, MRK",
            "features": {
                "keywords": [
                    "Health Care",
                    "Sector Update",
                    "ABBV",
                    "BLCM",
                    "EPZM",
                    "MRK"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 03/13/2018: ABBV, BLCM, EPZM, MRK",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-03-13",
            "original_text": "How AstraZeneca’s CVMD Segment Products Performed in 4Q17",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "CVMD",
                    "Segment Products",
                    "4Q17"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "How AstraZeneca’s CVMD Segment Products Performed in 4Q17",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-03-13",
            "original_text": "AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Positive Topline Results",
                    "Phase 3 Study",
                    "Elagolix",
                    "Uterine Fibroids"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]